RxDoctor Payments Data

Chinyere Mbaeri, MD

Family Medicine · Wellington, FLNPI 1912054297

Payments from drug & device makers

$5,688in general payments, 2019–2025

Across 118 payments — averaging $48.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Johnson & Johnson$2K
  • GSK$478
  • Gilead$438
  • Lilly USA, LLC$209
  • Pfizer$153
  • plus $571 from 14 others

What the payments were for

  • Food & beverage$5,688100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,688 in reported general payments places this provider in the 85th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$69,980
Medicare patients
205
Services billed
771

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban40$31,693
OzempicSemaglutide21$21,508
MounjaroTirzepatide12$12,691
FarxigaDapagliflozin Propanediol13$11,449
ShingrixVaricella-Zoster Ge/As01b/Pf15$3,365
Omega-3 Acid Ethyl Esters14$1,916
Atorvastatin Calcium126$1,532
Rosuvastatin Calcium50$1,186
Levothyroxine Sodium96$1,101
LantusInsulin Glargine,hum.Rec.Anlog14$1,007
Amlodipine Besylate124$977
Gemfibrozil26$956
Losartan Potassium75$935
Midodrine Hcl14$935
Nifedipine ErNifedipine17$829

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$153$31,69340 claims
Novo NordiskOzempic$152$21,50821 claims
Lilly USA, LLCMounjaro$209$12,69112 claims
AstraZenecaFarxiga$2,305$11,44913 claims
GSKShingrix$478$3,36515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Wellington

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →